Fragmento

GERD, BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA Surveys have shown that 10% to 20% of adults in the general population of Western countries experience heartburn, the cardinal symptom of gastroesophageal reflux disease (GERD), at least once a week. It has been estimated that Americans spend $9.3 billion each year for the evaluation and treatment of GERD. Chronic GERD can result in Barrett’s esophagus, the condition in which an abnormal intestinal-type epithelium replaces reflux-damaged esophageal squamous epithelium, and GERD and Barrett’s esophagus are the major risk factors for esophageal adenocarcinoma. The incidence of esophageal adenocarcinoma in the United States has increased by more than 600% since 1975, far outpacing the rising incidence of other tumors like melanoma and prostate cancer. Both Barrett’s esophagus and esophageal adenocarcinoma have a strong predilection for white men, and patients with Barrett’s esophagus develop esophageal adenocarcinoma at the rate of approximately 0.5% per year. Some proposed explanations for the rising incidence of esophageal adenocarcinoma are discussed below.

Palabras clave: Gastroesophageal Reflux Disease (GERD).

2007-09-04   |   1,259 visitas   |   Evalua este artículo 0 valoraciones

Vol. 72 Núm.2. Agosto 2007 Pags. 12-18 Rev Gastroenterol Mex 2007; 72(Supl. 1)